Clinical Trials Logo

Helicobacter Infections clinical trials

View clinical trials related to Helicobacter Infections.

Filter by:

NCT ID: NCT05775120 Recruiting - Gastric Cancer Clinical Trials

Epidemiology of Helicobacter Pylori Infection in Moscow

Start date: July 1, 2022
Phase:
Study type: Observational

H. pylori is transmitted from individual to individual and causes chronic active gastritis in all infected people. H. pylori infection can result in gastroduodenal ulcers, atrophic gastritis (AG), gastric carcinoma, and gastric MALT lymphoma. More than 90% of gastric carcinomas are linked to H. pylori infection that causes chronic AG. A long course of the disease leads to the loss of gastric glands (chronic AG) followed by gastric intestinal metaplasia (GIM), dysplasia, and cancer. This defines two cancer prevention strategies: primary that consists of detection and eradication of H. pylori and secondary that focuses on endoscopic screening for pre-neoplastic lesions and follow-up. Primary prevention planning requires reliable information on the H. pylori prevalence in the population. To design secondary prevention measures, an understanding of the age-sex structure of precancerous changes in the gastric mucosa (the prevalence of atrophic gastritis) is necessary. H. pylori eradication is the basis of primary prevention of gastric cancer (GC). Approximately 36,000 new cases of GC are registered in the Russian Federation each year, and more than 34,000 patients die from the disease. Men get sick 1.3 times more often than women, the peak incidence occurs at the age of over 50 years. The poor outcomes reflect the late stage of diagnosis of this potentially preventable and treatable cancer. The lack of up-to-date data on the H. pylori prevalence in Moscow hinders developing of measures for the detection and timely treatment of this infection as well as the reduction of GC morbidity and mortality.

NCT ID: NCT05762991 Recruiting - Clinical trials for Helicobacter Pylori Infection

Application of Artificial Intelligence on the Diagnosis of Helicobacter Pylori Infection and Premalignant Gastric Lesion

Start date: December 24, 2021
Phase:
Study type: Observational

The aim of this diagnostic accuracy study is to evaluate the application of artificial intelligence on the diagnosis of Helicobacter pylori infection and premalignant gastric lesions based on upper endoscopic images. We use techniques of artificial intelligence to analyze the correlation between endoscopic images and urea breath test results/histopathological results.

NCT ID: NCT05749081 Active, not recruiting - Clinical trials for Helicobacter Pylori Infection

Helicobacter Pylori and Lacidophilin Tablets in Combination With Vonorazan Dual Therapy

Start date: May 13, 2023
Phase: Phase 4
Study type: Interventional

Our previous study included 119 Helicobacter pylori(H. pylori)-infected Chinese patients without previous eradication history who were randomized to low-or high-dose amoxicillin-vonoprazan regimens consisting of amoxicillin 1 gram either b.i.d. or t.i.d plus vonoprazan 20 mg b.i.d for 7 or 10 days. Neither 7-or 10-day VA dual therapy with either b.i.d. or t.i.d. amoxicillin achieved satisfied efficacy (i.e., <90%) when given as first-line treatment for H. pylori infection. Lacidophilin tablets have been reported to increase the eradication rate of H. pylori while reducing the incidence of adverse effects.This study evaluated the efficacy and safety of lacidophilin tablets in combination with amoxicillin-vonoprazan dual therapy for 10 days as first-line treatment for H. pylori in China.

NCT ID: NCT05726734 Not yet recruiting - Clinical trials for Helicobacter Pylori Infection

Vonoprazan-containing Triple Therapy Versus Empiric Bismuth Quadruple Therapy for First-line Helicobacter Pylori Treatment: a Randomized Clinical Trial

Start date: February 6, 2023
Phase: Phase 4
Study type: Interventional

Vonoprazan Amoxicillin and metronidazole based triple therapy had achieved a high cure rate in the rescue treatment of helicobacter pylori infection. This study aims to evaluate the efficacy and safety of the Vonoprazan, amoxicillin and metronidazole based triple therapy and the empiric bismuth quadruple therapy in the naive patients with Helicobacter pylori infection.

NCT ID: NCT05718609 Recruiting - Clinical trials for Helicobacter Pylori Infection

Efficacy of Therapy Based on Fecal Molecular Antimicrobial Susceptibility Tests for Helicobacter Pylori Infection

Start date: March 1, 2023
Phase: Phase 4
Study type: Interventional

This study aims to evaluate the efficacy and safety of 14-day quadruple therapy based on fecal molecular antimicrobial susceptibility tests for the first-line eradication of H. pylori infection, thus, providing more evidence to inform the value of fecal antimicrobial susceptibility tests in the first-line treatment of H. pylori infection.

NCT ID: NCT05674864 Not yet recruiting - Clinical trials for Persistent Helicobacter Pylori Infection

Effect of Probiotics on Eradication of Persistent H.Pylori Infection

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

This study aims to investigate the possible safety and efficacy of probiotics (Bifidobacterium Infants, Enterococcus Feacium, and Lactobacillus Acidophilus) on the eradication rate of Helicobacter pylori and the incidence of adverse effects (AEs) of the concurrent rescue regimen in a patient with persistent H. Pylori infection.

NCT ID: NCT05654857 Recruiting - Clinical trials for Helicobacter Pylori Infection

The Prevalence of Family-unit Helicobacter Pylori Infection in Jiangsu

Start date: March 1, 2023
Phase:
Study type: Observational

To assess Family-unit Helicobacter Pylori Infection rates and antimicrobial resistance rates in Jiangsu,China

NCT ID: NCT05647278 Active, not recruiting - Clinical trials for Helicobacter Pylori Infection

A RCT of the Efficacy of Tegoprazan 50mg QD in the Treatment of Helicobacter Pylori Infection ( TATH-1 )

TATH-1
Start date: November 1, 2022
Phase: Phase 4
Study type: Interventional

The treatment of helicobacter pylori is very important. The routine treatment is quadruple therapy. In recent years, double therapy has appeared and the curative effect is fair. However, antacid generally uses proton pump inhibitor. The proton pump inhibitor needs double dose to achieve good antacid curative effect. The effect of Tegoprazan used for inhibiting gastric acid is better than proton pump inhibitor. At present, some studies use Tegoprazan instead of common proton pump inhibitor, but almost all use double dose of Tegoprazan. In the previous study, we found that the effect of double dose of proton pump inhibitor can be achieved with 50mg QD of Tegoprazan. Therefore, in this study, 50mg QD of Tegoprazan was used to replace the double dose of proton pump inhibitor to observe the antibacterial effect of Tegoprazan on Helicobacter pylori.

NCT ID: NCT05620602 Not yet recruiting - Clinical trials for Helicobacter Pylori Infection

The Effect of Time Intervals for Rescue Treatment on Eradication Effect of Helicobacter Pylori Infection

Start date: November 11, 2022
Phase:
Study type: Observational

The researchers collect patients who accepted eradication program of the helicobacter pylori but failed to eradicate helicobacter pylor from the outpatient clinic. After rescue therapy, evaluating the effect of retreatment interval on eradication effect of Helicobacter pylori infection.

NCT ID: NCT05620589 Not yet recruiting - Clinical trials for Helicobacter Pylori Infection

The Effect of Time Intervals for Rescue Treatment on Eradication Effect of Helicobacter Pylori Infection

Start date: November 11, 2022
Phase:
Study type: Observational

The researchers collect patients who accepted eradication program of the helicobacter pylori but failed to eradicate helicobacter pylor from the outpatient clinic. After rescue therapy, evaluating the effect of retreatment interval on eradication effect of Helicobacter pylori infection.